Remove 2019 Remove Drug Research Remove Packaging
article thumbnail

Deliberate Dysentery

Codon

With hepatitis C, what changed within the last 10 years was the development of direct-acting antivirals , or DAAs, which are packaged into pills that you can take once a day for a few months. There have been deaths in phase 1 medical and drug research among healthy participants. AP: Human challenge trials supported the F.D.A.

Vaccine 111
article thumbnail

Overcoming inefficiencies to improve access to cell and gene therapy 

Drug Discovery World

Before 2019, CGT drug developers still had a young, academic mindset, ordering reagents, materials, and equipment haphazardly and assuming they would show up when needed. So, what are the most promising tactics for increasing public access to CGTs?  Reducing manufacturing costs may help significantly in bringing drug costs down.

Therapies 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Article EMA Thank You With all nitrosamines deadlines passed, EMA updates its guidelines

Agency IQ

By early 2019, it became apparent that NDMA was not the only nitrosamine forming in API synthesis. EMA’s investigation ended up revealing even more causes of nitrosamine impurities in drugs, discovering, for example , that formation happened during the heat-sealing process of in certain products using blister-packaging.

article thumbnail

How big data analytics can make personalised care a reality

Drug Discovery World

Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care. 2019 Nov 10;60(13):3161-71. Leukemia & Lymphoma.

article thumbnail

Analysis Life Sciences Thank You FDA lays out new assessment framework for certain nitrosamines

Agency IQ

By early 2019, it became apparent that NDMA was not the only nitrosamine forming in API synthesis. drug supply, manufacturers should conclude a risk assessment of approved or marketed products within 6 months of publication of this guidance,” FDA added, with confirmatory testing intended to be concluded within 3 years.

FDA 40